• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Ovid Therapeutics (OVID)

Common Shares
Sell: $1.59|Buy: $1.64|Change: 0.05 (-3.03%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Find out more

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with apotential best-in-class mechanism of action.

Address

1460 Broadway
Suite 15044
New York
NY
USA
10036

Website

https://www.ovidrx.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Ovid Therapeutics Inc Second Quarter Earnings Results for 20262026-08-13T00:00:00
Ovid Therapeutics Inc Annual General Meeting for 20262026-07-09T10:30:00
Ovid Therapeutics Inc First Quarter Earnings Results for 20262026-05-13T00:00:00
Ovid Therapeutics Inc Fourth Quarter Earnings Results for 20252026-03-11T00:00:00
Ovid Therapeutics Inc Annual Report for 20252026-03-11T00:00:00
Ovid Therapeutics Inc Third Quarter Earnings Results for 20252025-11-12T00:00:00
Ovid Therapeutics Webcast to Discuss OV329 Phase 1 Topline Results2025-10-03T08:30:00

Previous key dates

NameKey Date
Ovid Therapeutics Webcast to Discuss OV329 Phase 1 Topline Results2025-10-03T08:30:00
Ovid Therapeutics Inc Second Quarter Earnings Results for 20252025-08-13T00:00:00
Ovid Therapeutics Inc Annual General Meeting for 20252025-07-09T10:30:00
Biomarkers in Epilepsy Investor Event2025-06-12T09:30:00
Ovid Therapeutics Inc First Quarter Earnings Results for 20252025-05-13T00:00:00
24th Annual Needham Virtual Healthcare Conference2025-04-07T08:45:00
Ovid Therapeutics Inc Fourth Quarter Earnings Results for 20242025-03-11T00:00:00
Ovid Therapeutics Inc Annual Report for 20242025-03-11T00:00:00
TD Cowen 45th Annual Health Care Conference2025-03-03T15:10:00
Oppenheimer 35(th) Annual Healthcare Life Sciences Conference2025-02-12T16:00:00
Ovid Therapeutics Inc Third Quarter Earnings Results for 20242024-11-12T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.